Research ArticleDrug Discovery

Computational Repositioning of the Anticonvulsant Topiramate for Inflammatory Bowel Disease

See allHide authors and affiliations

Science Translational Medicine  17 Aug 2011:
Vol. 3, Issue 96, pp. 96ra76
DOI: 10.1126/scitranslmed.3002648

eLetters is an online forum for ongoing peer review. Submission of eLetters are open to all. Please read our Terms of Service before submitting your own eLetter.

Compose eLetter

Plain text

  • Plain text
    No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

  • Is a single type of data sufficient for accurate computational drug repositioning?


    We read with interest the article by Dudley et al, "Computational Repositioning of the Anticonvulsant Topiramate for Inflammatory Bowel Disease". The authors used a single type of data, namely public microarray data, to create gene expression signatures for drugs and diseases, and compared these signatures to arrive at novel repositioning candidates for Inflammatory Bowel Disease (IBD). They found topiramat...

    Show More
    Competing Interests: None declared.

Stay Connected to Science Translational Medicine